Low density lipoprotein future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
====Antisense Oligonucleotides==== | ====Antisense Oligonucleotides==== | ||
====Small Interfering RNAs==== | ====Small Interfering RNAs==== | ||
===Microsomal Triglyceride Transfer Protein | ===Microsomal Triglyceride Transfer Protein (MTP) Inhibition=== | ||
===Thyromimetics=== | ===Thyromimetics=== | ||
===Squalene Synthase Inhibition=== | ===Squalene Synthase Inhibition=== | ||
==References== | ==References== | ||
Revision as of 12:18, 2 October 2013
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Low density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Low density lipoprotein future or investigational therapies |
|
FDA on Low density lipoprotein future or investigational therapies |
|
CDC on Low density lipoprotein future or investigational therapies |
|
Low density lipoprotein future or investigational therapies in the news |
|
Blogs on Low density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for Low density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Investigational Therapies
Inhibition of Apolipoprotein B production
PCSK9 Inhibition
Monoclonal Antibodies
Antisense Oligonucleotides
Small Interfering RNAs
Microsomal Triglyceride Transfer Protein (MTP) Inhibition
Thyromimetics
Squalene Synthase Inhibition
References